International centre for biomedical research and technology and affiliated institutions chose supplier of non-radioactive-labelled nucleotides
PerkinElmer Life and Analytical Sciences has announced it has been selected by Amdec Foundation to supply key non-radioactive-labelled nucleotides for its affiliated institutions at a significant saving.
Amdec was developed by leaders in New York's medical and scientific community to establish New York as the international centre for biomedical research and technology over the next decade.
Through Amdec, its 39 affiliated institutions are working collaboratively to develop large-scale basic science and clinical research projects, expand New York's research infrastructure, recruit talented researchers to New York's scientific institutions, and pursue research-related business opportunities.
This agreement with PerkinElmer represents Amdec's first agreement pertaining to microarray reagents, and continues Amdec's mission to develop business relationships that foster more cost-effective research.
"One of the major goals of Amdec is the standardisation of operating procedures among the member institutions.
Our agreement with PerkinElmer will provide Amdec members easier access and better pricing on some of the most critical components needed for our microarray-based research," said Maria K Mitchell, president of Amdec. "PerkinElmer's long standing reputation in the area of quality labelled nucleotides was one of the major reasons for establishing this agreement, which will ultimately help Amdec realise its objectives," said Andrew Brooks, director of the Functional Genomics Center at the University of Rochester Medical Center, who leads Amdec's microarray resource initiative. "This opportunity to work with Amdec represents an unprecedented relationship, allowing PerkinElmer to play a pivotal role in assisting the New York health and sciences community in standardising their microarray protocols," said Peter Coggins, president of PerkinElmer Life and Analytical Sciences.
"This agreement further demonstrates our commitment to providing quality products and services to organisations looking to enhance their research programmes." PerkinElmer will offer Amdec affiliated-institutions its proprietary nucleotide analogues, including array-certified cyanine- and biotin-labelled nucleotides.
These products enable rapid, simultaneous screening of many genes.
